Abstract
G protein-coupled CB1 cannabinoid receptors are found in high density in the nervous system. CB1 cannabinoid receptors have the ability to change conformation between inactive and active receptor states in the absence of agonists. The ability to adopt an active conformation in the absence of agonists results in constitutive receptor signaling. Inverse agonists reverse the constitutive activity of the receptor in the absence of agonists also antagonize receptor activity due to the presence of agonists. This dual effect of the CB1 cannabinoid receptor inverse agonist SR141716A is a result of its ability to bind both inactive and active receptors, but with a relatively higher affinity for the inactive receptor. The higher affinity of SR141716A for the inactive receptor is due to its ability to hydrogen bond to lysine 3.28 in transmembrane helix 3, a residue available to SR141716A only in the inactive state.
Keywords: Protein-Coupling, transmembrane, SR141716A
Current Neuropharmacology
Title: Cannabinoid Receptor G Protein-Coupling and Inverse Agonism
Volume: 2 Issue: 1
Author(s): Deborah L. Lewis
Affiliation:
Keywords: Protein-Coupling, transmembrane, SR141716A
Abstract: G protein-coupled CB1 cannabinoid receptors are found in high density in the nervous system. CB1 cannabinoid receptors have the ability to change conformation between inactive and active receptor states in the absence of agonists. The ability to adopt an active conformation in the absence of agonists results in constitutive receptor signaling. Inverse agonists reverse the constitutive activity of the receptor in the absence of agonists also antagonize receptor activity due to the presence of agonists. This dual effect of the CB1 cannabinoid receptor inverse agonist SR141716A is a result of its ability to bind both inactive and active receptors, but with a relatively higher affinity for the inactive receptor. The higher affinity of SR141716A for the inactive receptor is due to its ability to hydrogen bond to lysine 3.28 in transmembrane helix 3, a residue available to SR141716A only in the inactive state.
Export Options
About this article
Cite this article as:
Lewis L. Deborah, Cannabinoid Receptor G Protein-Coupling and Inverse Agonism, Current Neuropharmacology 2004; 2 (1) . https://dx.doi.org/10.2174/1570159043476891
DOI https://dx.doi.org/10.2174/1570159043476891 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Nitric Oxide and Schizophrenia: Present Knowledge and Emerging Concepts of Therapy
CNS & Neurological Disorders - Drug Targets [177Lu]-DOTA0-Tyr3-Octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma
Current Radiopharmaceuticals Confocal Microscopy Evidence of Prion Protein Fragment hPrP[173-195] Internalization in Rat B104 Neuroblastoma Cell Line
Protein & Peptide Letters Experimental and Clinical Advances in Immunotherapy Strategies for Spinal Cord Injury Target on MAIs and Their Receptors
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Aging Science AICD Nuclear Signaling and Its Possible Contribution to Alzheimers Disease
Current Alzheimer Research Neuroprotection for Amyotrophic Lateral Sclerosis: Role of Stem Cells, Growth Factors, and Gene Therapy
Central Nervous System Agents in Medicinal Chemistry Raf Inhibitors as Therapeutic Agents Against Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets The Dynamic TRPA1 Channel: A Suitable Pharmacological Pain Target?
Current Pharmaceutical Biotechnology Why and how do Microbubbles Enhance the Effectiveness of Diagnostic and Therapeutic Interventions in Cerebrovascular Disease?
Current Pharmaceutical Design Therapeutic Trials in Human Transmissible Spongiform Encephalopathies: Recent Advances and Problems to Address
Infectious Disorders - Drug Targets Alzheimers Disease: SPECT and PET Tracers for Beta-Amyloid Imaging
Current Alzheimer Research Role of Nitric Oxide Signaling Pathways in Brain Injuries
Current Chemical Biology Somatic Mosaicism in Cases with Small Supernumerary Marker Chromosomes
Current Genomics Role of the Transglutaminase Enzymes in the Nervous System and their Possible Involvement in Neurodegenerative Diseases
Current Medicinal Chemistry Reactive Astrocytes as Potential Manipulation Targets in Novel Cell Replacement Therapy of Parkinsons Disease
Current Drug Targets Therapeutic Potential of Hepatocyte Growth Factor for Treating Neurological Diseases
Current Drug Therapy Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities
Current Medicinal Chemistry Adult Neurogenesis and the Diseased Brain
Current Medicinal Chemistry Non-Selective Cation Channel Blockers: Potential Use in Nervous System Basic Research and Therapeutics
Mini-Reviews in Medicinal Chemistry